Efficacy of a Combination of Tanacetum parthenium, 5-Hydroxy Tryptophan and Magnesium (Aurastop) in Episodic Migraine Prevention: A Multicentric Observational Study ()
Affiliation(s)
1Headache Centre, Neurological Division, SS Giovanni e Paolo Hospital, Venice, Italy.
2Headache Centre of Neurological Division of Gavazzeni Hospital, Bergamo, Italy.
3Headache Centre, Department of Neurosciences, Padua University, Padua, Italy.
4Headache Center of Neurological Unit of Istituto Clinico Città di Brescia, Brescia, Italy.
ABSTRACT
Objective: To verify the efficacy and safety of the new combination of Tanacetum parthenium 150 mg, 5-hydrossitriptophan (5-HTTP) 20 mg and magnesium 185 mg (Aurastop) in the prophylactic treatment of episodic migraine without aura (MO). Methods: Eighty patients suffering from MO for at least 6 months with a monthly frequency of 3 to 8 attacks and 4 to12 headache days, were enrolled in this open study and treated with Aurastop twice daily per os for 3 months. The reduction of headache days per month was assessed as the primary end-point, while the secondary end-points were: 1) reduction of the number of MO attacks; 2) reduction of intensity of the pain; 3) reduction of acute treatment drug intake; 4) subjective change of pain intensity. Results: All the parameters significantly improved at the end of the observational period of treatment with Aurastop. In more detail: a significant reduction of the number of headache days (from 9.1 ± 2.0 before treatment to 3.2 ± 1.8 post treatment, p < 0.001); number of attacks per month (from 6.0 ± 1.2 to 2.4 ± 1.1, p < 0.001); pain intensity (in a visual analogical scale [VAS]: from 7 ± 1.0 to 3.2 ± 0.7, p < 0.001); number of drug doses for acute treatment (triptans, simple analgesics or in combination) assumed by each subject per month (from 9.5 ± 1.8 to 2.2 ± 1.1, p < 0.001). No serious adverse events were observed. Conclusion: Albeit obtained with the limitation of open-trials, our findings suggest that AURASTOP is a promising approach for migraine prevention; further investigations are required to confirm the safety and efficacy of this treatment.
Share and Cite:
Mainardi, F. , Merlo, P. , Maggioni, F. , Zanchin, G. and Volta, G. (2018) Efficacy of a Combination of Tanacetum parthenium, 5-Hydroxy Tryptophan and Magnesium (Aurastop) in Episodic Migraine Prevention: A Multicentric Observational Study.
Open Access Library Journal,
5, 1-9. doi:
10.4236/oalib.1104765.